GlassScriptPhysician profile
Amit A Patel
NPI 1306098827
$770,208.18
in general payments reported to CMS, 2019-2025
74 companies · $166K in 2025
The $166K reported for 2025 was more than what 99% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $82K · 2020: $78K · 2021: $109K · 2022: $88K · 2023: $84K · 2024: $164K · 2025: $166K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $372K · Travel and Lodging: $15K · Food and Beverage: $13K · Consulting Fee: $8,893 · Honoraria: $4,550 · Long Term Medical Supply Or Device Loan: $167 · Education: $69.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $371,749.00 |
| Travel and Lodging | $15,249.87 |
| Food and Beverage | $12,605.07 |
| Consulting Fee | $8,892.50 |
| Honoraria | $4,550.00 |
| Long Term Medical Supply Or Device Loan | $166.66 |
| Education | $69.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $279,019.68 | 2020-2025 | Enhertu, Datroway |
| Astrazeneca Pharmaceuticals LP | $146,256.63 | 2019-2025 | Enhertu, Datroway, Imfinzi |
| Incyte Corporation | $138,620.36 | 2019-2025 | Jakafi, Jakafi |
| Celgene Corporation | $132,044.39 | 2019-2024 | Reblozyl |
| Jazz Pharmaceuticals INC. | $45,723.24 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $12,029.52 | 2019-2025 | Pomalyst, Opdivo |
| Novocure INC. | $5,716.33 | 2020-2025 | Optune Lua (Novottf-200t) |
| Cti Biopharma Corp. | $2,538.19 | 2022-2023 | Vonjo |
| Novartis Pharmaceuticals Corporation | $1,165.58 | 2019-2025 | |
| Amgen INC. | $544.97 | 2019-2023 | Kyprolis, Blincyto |
| Janssen Biotech, INC. | $541.38 | 2019-2025 | Erleada, Tecvayli, Talvey |
| Merck Sharp & Dohme LLC | $466.03 | 2019-2024 | Keytruda, Lynparza |
| Astellas Pharma US INC | $372.66 | 2019-2025 | Xtandi, Xospata, Vyloy |
| Seagen INC. | $329.12 | 2019-2023 | Tukysa |
| Adaptive Biotechnologies Corporation | $324.77 | 2024-2025 | Clonoseq |
Show all 74 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amit Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.